Bright Minds Biosciences (DRUG) Competitors $38.88 -3.75 (-8.80%) Closing price 04:00 PM EasternExtended Trading$39.70 +0.82 (+2.11%) As of 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRUG vs. PHVS, GPCR, TLRY, RCUS, LENZ, ZYME, SYRE, UPB, STOK, and VERVShould you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include Pharvaris (PHVS), Structure Therapeutics (GPCR), Tilray Brands (TLRY), Arcus Biosciences (RCUS), LENZ Therapeutics (LENZ), Zymeworks (ZYME), Spyre Therapeutics (SYRE), Upstream Bio (UPB), Stoke Therapeutics (STOK), and Verve Therapeutics (VERV). These companies are all part of the "pharmaceutical products" industry. Bright Minds Biosciences vs. Its Competitors Pharvaris Structure Therapeutics Tilray Brands Arcus Biosciences LENZ Therapeutics Zymeworks Spyre Therapeutics Upstream Bio Stoke Therapeutics Verve Therapeutics Pharvaris (NASDAQ:PHVS) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends. Do insiders and institutionals believe in PHVS or DRUG? 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, PHVS or DRUG? Pharvaris has a beta of -2.81, indicating that its stock price is 381% less volatile than the S&P 500. Comparatively, Bright Minds Biosciences has a beta of -6.07, indicating that its stock price is 707% less volatile than the S&P 500. Which has better valuation & earnings, PHVS or DRUG? Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharvarisN/AN/A-$145.24M-$3.36-6.44Bright Minds BiosciencesN/AN/A-$2.06M-$0.93-41.81 Do analysts rate PHVS or DRUG? Pharvaris presently has a consensus price target of $35.60, indicating a potential upside of 64.43%. Bright Minds Biosciences has a consensus price target of $83.25, indicating a potential upside of 114.12%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Bright Minds Biosciences is more favorable than Pharvaris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharvaris 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is PHVS or DRUG more profitable? Bright Minds Biosciences' return on equity of -20.96% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets PharvarisN/A -69.09% -63.34% Bright Minds Biosciences N/A -20.96%-20.66% Does the media refer more to PHVS or DRUG? In the previous week, Bright Minds Biosciences had 1 more articles in the media than Pharvaris. MarketBeat recorded 5 mentions for Bright Minds Biosciences and 4 mentions for Pharvaris. Bright Minds Biosciences' average media sentiment score of 0.99 beat Pharvaris' score of 0.75 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bright Minds Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBright Minds Biosciences beats Pharvaris on 12 of the 14 factors compared between the two stocks. Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRUG vs. The Competition Export to ExcelMetricBright Minds BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$273.72M$3.07B$5.76B$9.74BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-41.8120.9031.4426.41Price / SalesN/A355.29431.79159.14Price / CashN/A44.7137.7559.42Price / Book7.318.0410.566.60Net Income-$2.06M-$53.98M$3.27B$265.83M7 Day Performance-11.56%-0.85%0.60%0.18%1 Month Performance11.66%5.68%5.44%2.14%1 Year Performance3,638.46%9.07%50.34%21.00% Bright Minds Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRUGBright Minds Biosciences2.4286 of 5 stars$38.88-8.8%$83.25+114.1%+3,775.5%$273.72MN/A-41.81N/APHVSPharvaris2.3547 of 5 stars$22.16-0.6%$35.60+60.6%+27.2%$1.17BN/A-6.6030GPCRStructure Therapeutics2.8578 of 5 stars$19.96-0.8%$75.71+279.3%-51.4%$1.16BN/A-19.01136Positive NewsTLRYTilray Brands2.2143 of 5 stars$1.14+10.7%$1.92+68.1%-13.5%$1.13B$821.31M-0.492,842Trending NewsOptions VolumeGap DownRCUSArcus Biosciences2.393 of 5 stars$10.45+0.6%$21.14+102.3%-38.5%$1.11B$258M-3.30500News CoveragePositive NewsLENZLENZ Therapeutics2.0015 of 5 stars$38.77+2.4%$49.60+27.9%+72.9%$1.08BN/A-20.41110ZYMEZymeworks0.0737 of 5 stars$14.05-2.2%N/AN/A$1.08B$76.30M-14.48460SYRESpyre Therapeutics3.0779 of 5 stars$16.94-0.1%$53.40+215.2%-40.3%$1.02B$890K-4.9873News CoveragePositive NewsUPBUpstream Bio2.3229 of 5 stars$18.02-4.8%$56.50+213.5%N/A$1.02B$2.37M0.0038News CoveragePositive NewsSTOKStoke Therapeutics4.497 of 5 stars$18.51+1.6%$25.57+38.1%+44.0%$997.86M$36.56M21.78100Positive NewsVERVVerve Therapeutics2.737 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110 Related Companies and Tools Related Companies Pharvaris Competitors Structure Therapeutics Competitors Tilray Brands Competitors Arcus Biosciences Competitors LENZ Therapeutics Competitors Zymeworks Competitors Spyre Therapeutics Competitors Upstream Bio Competitors Stoke Therapeutics Competitors Verve Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRUG) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access